Neurosense Therapeutics Ltd reports results for the quarter ended September 30 - Earnings Summary

• Neurosense Therapeutics Ltd NRSN.OQ reported a quarterly adjusted loss of 11 cents​​ per share for the quarter ended September 30, lower than the same quarter last year, when the company reported EPS of 10 cents. The mean expectation of two analysts for the quarter was for a loss of 16 cents per share. Wall Street expected results to range from -21 cents to -11 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Neurosense Therapeutics Ltd's reported EPS for the quarter was a loss of 11 cents​.

• The company reported a quarterly loss of $2.15 million.

• Neurosense Therapeutics Ltd shares had fallen by 14.2% this quarter and gained 38.9% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 23.8% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is "hold."

Wall Street's median 12-month price target for Neurosense Therapeutics Ltd is $7.50

This summary was machine generated from LSEG data December 18 at 05:27 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)